Determination of Bacillus Calmette-Guerin Concentration Integrated in Delivery Materials for Intravesical Infusion Therapy of Superficial Bladder Cancer

Abstract:

Purpose: To assess determination of Bacillus Calmette-Guerin(BCG) concentration integrated in delivery materials for intravesical infusion therapy of superficial bladder cancer. Material and Methods: The standard BCG solution was prepared and divided into two groups. One group was measured by spectrophotometer direct, the other group was determined by using enzyme mark instrument after the solution had cultured. The preliminary experiment study on BCG integrated delivery materials was finished by XTT method. Results: The wavelength of the characteristic peak changes with the variety of the concentration measured by spectrophotometer direct. The concentration of BCG which was embeded in integrated delivery materials for intravesical infusion therapy of superficial bladder cancer was linear with absorbance at 450nm by XTT method in the selected range. Conclusions: It is an incorrect way to measure BCG concentration like determining other solutions by the spectrophotometer immediately and direct. It is the simple, rapid and reliable method by XTT method to study on the performance of the BCG concentration integrated in delivery materials for Intravesical infusion therapy of superficial bladder cancer.

• Periodical: Advanced Materials Research (Volumes 655-657)
• Pages: 1917-1922
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.655-657.1917
• Online since: January 2013
• Authors: Cheng Ge Wu, Kang Ning Sun, Ai Min Li, Xiao Ning Sun
• Keywords: BCG, Bladder Tumor, Invasive, Superficial Recurrence

References

[1] Grasso, M.: Bladder Cancer: A Major Public Health Issue. European Urology Supplements, 7(7) (2008), pp.510-515.

DOI: 10.1016/j.eursup.2008.04.001

[2] Phull, J.S., et al.: Modern transurethral resection in the management of superficial bladder tumours. British Journal of Medical and Surgical Urology, 4(3) (2011), pp.91-100.

DOI: 10.1016/j.bjmsu.2010.11.004

[3] van der Heijden, A.G. and J.A. Witjes: Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer. European Urology Supplements, 8(7) (2009), pp.556-562.

DOI: 10.1016/j.eursup.2009.06.010

[4] Behnsawy, H.M., et al.: Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Urologic Oncology: Seminars and Original Investigations, 29(5) (2011).

DOI: 10.1016/j.urolonc.2009.08.002

[5] Sylvester, R.J., A.P.M. van der Meijden, and D.L. Lamm: Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials. The Journal of Urology, 168(5) (2002).

DOI: 10.1016/s0022-5347(05)64273-5

[6] Urdaneta, G., E. Solsona, and J. Palou: Intravesical Chemotherapy and BCG for the Treatment of Bladder Cancer: Evidence and Opinion. European Urology Supplements, 7(7) (2008), pp.542-547.

DOI: 10.1016/j.eursup.2008.04.006

[7] Morales, A., D. Eidinger, and A.W. Bruce: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. The Journal of Urology, 116(2) (1976), pp.180-3.

DOI: 10.1016/s0022-5347(17)58737-6

[8] Yu, D. -S., et al.: The Feasibility of BCG and Sunitinib Combination Therapy for Transitional Cell Carcinoma. Urological Science, 22(1) (2011), pp.19-27.

DOI: 10.1016/s1879-5226(11)60004-3

[9] Simons, M.P., M.A. O'Donnell, and T.S. Griffith: Role of neutrophils in BCG immunotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 26(4) (2008), pp.341-345.

DOI: 10.1016/j.urolonc.2007.11.031

[10] O'Donnell, M.A.: Optimizing BCG therapy. Urologic Oncology: Seminars and Original Investigations, 27(3) (2009), pp.325-328.

DOI: 10.1016/j.urolonc.2008.10.024

[11] Wilson, J.R.F., et al.: A comparison of two BCG instillation regimens for non-muscle invasive bladder cancer: A retrospective cohort analysis of side effect profiles. British Journal of Medical and Surgical Urology, 3(6) (2010), pp.241-248.

DOI: 10.1016/j.bjmsu.2010.02.008

[12] Bunimovich-Mendrazitsky, S., J. Claude Gluckman, and J. Chaskalovic: A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer. Journal of Theoretical Biology, 277(1) (2011).

DOI: 10.1016/j.jtbi.2011.02.008

[13] Tanaka, N., et al.: Frequency of Tumor Recurrence: A Strong Predictor of Stage Progression in Initially Diagnosed Nonmuscle Invasive Bladder Cancer. The Journal of Urology, 185(2) (2011), pp.450-455.

DOI: 10.1016/j.juro.2010.09.087

[14] ai-hua, Z.: Tetrazolium salt assay for rapid determination of viable count of BCG vaccine. Chin Med Biotechnol, 4(1) (2009), p.4.